Introduction demonstrated that RevM10 can inhibit viral replication in Human immunodeficiency virus type-1 (HIV-1) encodes
HIV-infected T cell lines and primary T cells. [10] [11] [12] [13] [14] [15] several regulatory genes including Rev (reviewed in Refs Intracellular expression of genes which can suppress 1-3). Through binding to a structured RNA sequence, HIV-1 replication has been proposed as an alternative to termed the Rev-responsive element (RRE), Rev promotes standard therapies for the treatment of AIDS. 16, 17 A large the export of RRE-containing mRNAs from the nucleus 4, 5 number of antiviral genes including RNA decoys, antileading to cytoplasmic accumulation of incompletely sense RNA, transdominant mutants (including RevM10), spliced HIV-1 transcripts. First, these transcripts serve as ribozymes and intracellular antibodies (reviewed in Ref. templates for translation of viral proteins gag, pol and env.
16) have been shown to inhibit effectively HIV-1 in vitro. Second, the nonspliced genomic mRNA is needed for
The target cell population for delivery of anti-HIV genes infectious particle formation. HIV-1 Rev function requires could be peripheral blood mononuclear cells, 18, 19 or alterinteraction with one or more cellular host proteins.
inactivating LTR vectors and other LTR modifications, driven transcript ( Figure 2 , lower left panel) resulting in RevM10 protein levels approximately 10-fold higher than and insertion of an expression cassette into the LTR (double-copy vectors) (reviewed in Refs 21, 23). Despite internal promoter vectors ( Figure 3 ). No apparent difference between the MoMLV-LTR and MPSV-LTR vectors all these studies, the optimal vector design for the expression of a particular gene needs to be determined could be detected in CEMSS cells and the different primer binding sites also had no measurable impact. To empirically and the final result may depend on the combination of both gene and vector sequences. [24] [25] [26] further improve expression of the LTR-RevM10 vectors, the tk-Neo sequence was replaced by the SV40-Puro tranAs part of our efforts to develop clinical protocols for gene therapy of AIDS we have tested a number of retroscription unit (LMSPL vector; Figure 1 ). This modification resulted in a two-to three-fold increase in RevM10 viral vector designs to optimally express the transdominant RevM10 protein. In particular, we carefully anaprotein levels in CEMSS cells (compare LMTNL with LMSPL, Figure 3 ). lyzed vector expression in primary T cells at various stages of activation. We also evaluated the anti-HIV In all vectors ( Figure 1 ; numbers 4-8), the packaging signal is encoded by a short retroviral sequence 13, 36 and potency of selected vectors in chronically and acutely HIV-infected cell lines as well as in primary T cells. The the RevM10 protein is synthesized from an unspliced full-length messenger RNA. The presence of an intron in results suggest that the extent of inhibition of HIV-1 replication is a function of the relative expression of RevM10 a transcription unit can improve the expression of some cDNAs. 37 To test this possibility, we constructed RevM10 protein in those cells, supporting the hypothesis that RevM10 acts as an intracellular competitive inhibitor. . This finding was not surprising since the splicing in the MFG vector had been optimized for protein expression. 39 However, both vecRetroviral vector LTR-driven expression yields high steady-state levels of RevM10 protein in transduced tors yielded similar steady-state intracellular RevM10 protein levels and these were not significantly higher T cells We started our study by testing vectors in which RevM10 when compared to the intronless LMSPL vector ( Figure  2 ). Thus, inclusion of an intron did not further improve expression is driven by an internal promoter using the immediate-early promoter of the human cytomegaloRevM10 protein expression. An unexpected short Revspecific transcript was detected in the LMSPL RNA virus 27 (LNCML vector; Figure 1 ) and the mouse phosphoglycerate kinase gene promoter 28 (LNMPL and (Figure 2 ). This RNA is a splice product between the splice donor in the retroviral packaging sequence and a LPMPL vectors; Figure 1 ). Human CEMSS T lymphoid cells were transduced with amphotropic retroviral vecsplice acceptor located in the RevM10 coding sequence and does not encode functional RevM10 protein (data not tors harvested from PA317-based producer cells and selected either with G418 or puromycin to yield homoshown). As expected, a 10-fold higher virus titer was obtained with the LMSPL-INT1 vector because of the genous populations of transduced cells. RevM10 protein and RNA expression were analyzed by Rev-specific extended packaging sequence 38 ( Figure 1 ). immunofluorescence 29 and Northern blotting, respectively. Regardless of the internal promoter used, low RevM10 protein threshold level is required for inhibition of HIV-1 replication in chronically infected T cell lines RevM10 RNA expression levels were observed in transduced cells (Figure 2 ) which resulted in intracellular
We have used an assay system based on chronically HIVinfected A3.01/ProHygro T cells to compare the anti-HIV RevM10 protein levels barely detectable above background (Figure 3 ). Since it has been reported that the neoefficacy of the different vectors expressing various levels of the RevM10 protein. 13 The A3.01/ProHygro cells were mycin phosphotransferase gene (Neo) gene sequence can act as a transcriptional silencer, 30 we attempted to transduced by co-cultivation with the PA317-derived retroviral vector producer cells followed by selection in improve RevM10 expression by replacing the Neoresistance gene with the puromycin-resistance gene G418 and hygromycin. Established drug-resistant cell populations were analyzed for RevM10 protein (Puro) (LPMPL vector; Figure 1 ). This modification increased intracellular RevM10 RNA (Figure 2 ) and proexpression and for HIV-1 production kinetics. As negative control, we used vectors LNC⌬ML, and L⌬MTNL tein steady-state levels in CEMSS cells slightly, but the overall expression was still low (Figure 3 with the LNCML vector while the LMTNL, MPSVobtaining a minimum RevM10 threshold level was required for inhibition of HIV replication in this assay MTNL, MESV-MTNL, L/587-MTNL and LMSPL vectors produced RevM10 at levels two-to four-fold higher than system. the endogenous wild-type Rev protein (Table 1) . Interestingly, the LMSPL vector did not produce more RevM10
Antiviral effect of RevM10 is overcome at high HIV-1 inoculation dose protein than the LMTNL vector, which is in contrast to the results in CEMSS cells (compare Figure 3 and Table
In the A3.01/ProHygro assay system, HIV-1 is secreted at a constant rate and by using the retroviral vectors 1). We have observed RevM10 expression patterns similar to CEMSS cells in other cells lines (PA317, U937, data described above, we were able to express different amounts of the RevM10 antiviral protein. Table 1 ).
portional to the HIV-1 inoculation dose and was completely overcome at the highest inoculation dose MOI = Although the protein assay did not detect RevM10 in the LNCML-transduced cells it is likely that low levels of 0.
1. These experiments demonstrate that both the relative level of RevM10 expression and the viral burden are protein were produced which were not sufficient to demonstrate any anti-HIV effect. Hence it appears that important factors that influence antiviral efficacy.
healthy donors by depleting CD8 + cells using immunomagnetic beads yielding approximately 90% pure cell populations. Cells were stimulated with PHA, IL-2 and irradiated allogeneic feeder cells for 3-4 days and subsequently transduced with retroviral vectors by centrifugation. 43, 44 Following this protocol, we detected 4-8% Lyt-2 positive cells (data not shown) and after expansion in vitro, positive cells were further enriched to 70-80% purity using immunomagnetic beads. We have used the CD25 surface protein (low-affinity IL-2 receptor) as a marker for the activation status of T cells. Three to 5 days after stimulation with PHA, IL-2 and irradiated allogeneic feeder cells, CD25 expression was at maximum and starting to decline. By days 11-14, primary T cells ceased to proliferate and the CD25 marker was almost completely down-regulated reflecting the mitotically resting state of these cells (Figure 6b and 7) .
Interestingly, we have observed high Lyt-2 staining in activated T cells but transgene expression was low in resting cells. An example is shown in Figure 6b . No significant difference between the LMILy, MPSV-MILy, MESV-MILy and L/587-MILy vectors was detected. Lyt-2 staining in fully activated T cells was comparable to CEMSS cells (data not shown). Furthermore, we analyzed in detail the expression of various vectors relative to the activation status of T cells over the period of 11 days after stimulation. The kinetics of Lyt-2 expression followed exactly the expression pattern of the CD25 marker and again there was no difference between the four retroviral vectors tested (Figure 7) . . In fully activated LMILy-expressing cells ('day 5 restimulated'), HIV-1 replication was scent. We were interested in analyzing expression of the LMTNL, MPSV-MTNL, MESV-MTNL, and L/587-MTNL inhibited between day 5 and 7 and the extent of virusinhibition (approximately 1 log) was comparable to the vectors in PBLs at various stages of activation and proliferation (resting and activated PBLs). We modified the inhibition observed in transduced CEMSS cells ( Figure  5 ). In contrast, the RevM10-mediated anti-HIV effect was vectors by replacing the drug-resistance neomycin phosphotransferase gene with the Lyt-2 ␣′ surface marker 41 significantly reduced when transgene expression was not maintained (compare 'day 5' to 'day 5 restimulated', Fig-(Figure 6a , vectors LMILy, MPSV-MILy, MESV-MILy, L/587-MILy). In this vector design, both genes (RevM10 ure 8). Cells harvested on day 8 after stimulation did not support virus replication, in agreement with previous and Lyt-2) are encoded by a single bicistronic mRNA and the translation of the Lyt-2 is mediated by the internal observations that HIV-1 does not replicate well in nonactivated CD25 − T cells. 45, 46 ribosomal entry site (IRES) of the human encephalomyocarditis virus (EMCV). 42 Double-staining of transduced CEMSS and primary T cells for RevM10 and Lyt-2
Discussion
showed that the expression of the two proteins is colinear (data not shown). Therefore, Lyt-2 surface antigen
The focus of this study was to identify the optimal retroviral vector design to support maximal RevM10 protein expression directly correlates with expression of the RevM10 protein, and flow cytometric analysis of the surexpression in relevant target cells for HIV-1 infection. We have tested two basic vector structures: one design where face antigen can be used as a surrogate marker for RevM10 expression.
RevM10 is expressed from internal promoters and another based on retroviral LTR-directed RevM10 CD4
+ T cells were enriched from PBLs from normal expression. In addition to stability and titer, the RevM10 also in the monocyte-macrophage lineage (L Su, unpublished results). This finding corroborates previous studies retroviral vectors were evaluated for steady-state mRNA and intracellular RevM10 protein levels. Based on our reporting inhibition of HIV-1 replication using LTRdirected RevM10 expression in retrovirus-transduced T studies, LTR-based RevM10 vectors appear to be the optimal design for RevM10 expression not only in T cells but cell lines and primary T cells. 10, 11 A study by Bahner et
Figure 4 Comparison of the antiviral potency of various retroviral vectors in chronically HIV-infected A3.01/ProHygro cells. Growth kinetics of various vector-and control-transduced cells are shown in the upper panels. HIV-1 replication (lower panels) was measured as accumulation of p24 Gag protein in the culture supernatants over time. All values are average from duplicate samples. Vertical bars indicate standard errors (where not shown, the error was below resolution of the graphic program).
al 15 reported that a retroviral vector expressing the The panel of studied retroviral vectors enabled us to evaluate the effect of various RevM10 levels on virus repRevM10 gene from an internal CMV promoter yielded better antiviral efficacy in transduced CEM cells than a lication both in chronically and acutely HIV-infected cells. The concurrent assessment of intracellular RevM10 LTR-RevM10 vector. The actual steady-state RevM10 protein levels were not measured in this report and other protein concentration and antiviral efficacy suggests that relatively high levels of RevM10 are required to inhibit than different experimental conditions (HIV isolate, inoculation dose, cell line), we have no explanation for HIV replication. A3.01/ProHygro cells used in this study produce high titers of infectious HIV virus (10 5 TCID 50 this apparent discrepancy. We have previously demonstrated that CMV-directed RevM10 expression can suffice on CEMSS cells) 13 and express wild-type Rev protein at levels comparable to acutely infected CEMSS cells to block HIV-1 replication 14 albeit this particular vector expresses significantly lower intracellular RevM10 pro-(unpublished results). Data presented here clearly suggest that an excess of RevM10 protein over wild-type Rev tein levels than the LTR-RevM10 vectors described in this study. It is not excluded that promoters other than the is required for significant inhibition of HIV replication, supporting the hypothesis that RevM10 acts as a competi-LTR could express efficiently, in particular, in primary T cells. Indeed, our preliminary data show that the human tive inhibitor of Rev function. 9 HIV-1 replication was inhibited in RevM10-expressing CD4 gene promoter 47 inserted in a retroviral vector expresses transgenes in primary T cells although at lower activated primary T cells, as previously reported. 10, 11 However, the expression of retroviral vectors was downlevels than the LTR promoters (unpublished results). The differences in expression between the various retroviral regulated as the cells turned quiescent resulting in reduced ability to suppress HIV-1 replication. We have vectors could in part be due to differences in proviral copy number per cell, primarily because vectors with observed similar down-regulation of expression with vectors expressing the human NGF receptor 48 surface higher titers may infect target cells multiple times. However, we have not observed any correlation between the marker suggesting that this result is not specific to Lyt-2 or RevM10 proteins (unpublished results). Furthermore, viral titer and RevM10 expression (Figure 1 and Figure  3 ). For example, the vector LMSPL had a 20-fold lower preliminary RNA analysis suggests that RevM10 expression is controlled at the transcriptional level (data titer than the LMSPL-INT1 vector (Figure 1 ), but produced similar RevM10 protein levels (Figure 3) . Connot shown). MLV LTR-directed transgene expression exclusively relies on cellular transcription factors. In conversly, the LMTNL and the LMSPL vectors, which had comparable virus titers (3 × 10 6 and 2 × 10 6 c.f.u. per ml, trast, cellular factors (such as NF-B, NF-AT) are only required for HIV-1 basal gene expression (reviewed in respectively), produced different RevM10 protein levels (Figure 3) .
Ref . 1). Subsequently, the HIV-1-encoded Tat transactiv-
Figure 5 RevM10 antiviral efficacy is dose-dependent. CEMSS transduced with the LMTNL vector were inoculated with various doses of HIV-1 HXB3 virus, as indicated at the top of each panel. Virus replication was monitored over 14-15 days. A representative experiment is shown. Results were reproduced in two to four individual experiments. Vertical bars indicate standard error (where not shown, the error was below resolution of the graphic program). MOI, multiplicity of infection.
ator protein increases HIV-1 gene expression, resulting in or mouse hematopoietic stem cells. 24, 49 Our data suggest that in human primary T cells, MPSV or MESV-derived high steady-state viral RNA levels and protein synthesis (reviewed in Ref. 1). A possible explanation for our vectors have no advantage over MoMLV-based vectors with regard to transgene expression. Furthermore, conresults is that as T cells turned quiescent, active cellular transcription factors became less abundant and as a sidering that MoMLV-based vectors are expressed in human T cells 43 and monocyte-macrophages (Su et al, consequence retroviral vector expression was downregulated. In contrast, even low levels of transcription manuscript submitted) derived from transduced hematopoietic stem cells in SCID-hu mice, we propose that these factors could be sufficient to induce basal expression of HIV-1 LTR supporting Tat-mediated transactivation. Our vectors are good candidates for human stem cell-based gene therapy. MoMLV LTR-based retroviral vectors are results suggest that there is a window in time between fully activated and fully quiescent cells where HIV-1 can commonly used in preclinical experiments and have also been utilized in phase I clinical studies. 20, 51 Whether these still replicate, but recombinant retroviral vector expression is down-regulated to a level where the antivectors will maintain sufficient expression in vivo in differentiated target cells when introduced into human viral efficacy was measurably reduced. Although the activation status of HIV-infected T cells in vivo is being inveshematopoietic stem cells in gene therapy protocols needs to be studied. The results from the phase I human hematigated in many laboratories, our data indicate that improved transgene expression in nonactivated T cells topoietic stem cell clinical trials will help resolve these critical issues. will be an important factor to develop effective retroviral vector-based anti-HIV gene therapies.
Previously, MoMLV-LTR has been suspected as being
Materials and methods
a poor promoter for expression in hematopoietic cells 20, 21 and vectors derived from MPSV and MESV viruses were Vector constructions and retrovirus-producing cells The structures of recombinant retrovirus vectors are proposed as alternatives. 24, 34, 49, 50 However, these observations are from studies utilizing either stem cell lines 34, 50 shown in Figure 1 . LNCML was constructed by cloning the RevM10 cDNA 13 into the polylinker of the LNCX vecfragment spanning 5′LTR and packaging sequences, the NcoI-XhoI RevM10 fragment (NcoI site was engineered at tor.
38 LNMPL consist of the murine PGK promoter,
28
RevM10 gene and the murine PGK poly A signal 28 the Rev ATG) and the XhoI-SalI fragment from LMSPL spanning the SV40-Puro gene and the 3′LTR. Retroviral inserted in place of the CMV promoter fragment (NruI to HindIII) of LNCX. In LPMPL, the Neo gene fragment was vector plasmid DNAs were transfected into BOSC-23 cells as described. 54 Forty-eight hours after transfection, replaced by the puromycin resistance gene fragment.
52
The LMTNL vector was described previously. 13, 43 The BOSC-23 supernatants containing ecotropic retrovirus were used to inoculate PA317 cells. 55 Following transduc-LMTNL vector carries a variant of the MoMLV LTR which has one direct repeat in the enhancer region.
tion, PA317 cells were selected either in 600 g/ml G418 (Gibco-BRL, Gaithersburg, MD, USA) or 10 g/ml puro-LMTNL LTR is functionally indistinguishable from the MoMLV LTRs (unpublished results). MPSV-MTNL is mycin hydrochloride (Sigma, St Louis, MO, USA) to generate pools of producer cells. Retroviral titers were identical to the LMTNL, only the LTRs (NheI-KpnI fragment) are derived from MPSV (a gift from C Stockdetermined on NIH3T3 cells as described. 56 All producer cells were tested for the presence of replicationing, Heinrich-Pette-Institut, Hamburg, Germany). The L/587-MTNL and MESV-MTNL were derived by replaccompetent retrovirus by S+L− assay on PG4 cells. night in the presence of 2 g/ml polybrene and subsequently passaged twice daily for 3 days into new flasks gene in LXSN for the RevM10-SV40Puro fragment from LMSPL. The LMSPL-INT2 vector was constructed using to remove any adherent producer cells. Transduced cells were selected in medium containing either 2.5 g/ml purthree DNA fragments: the MFG-lacZ-derived 53 SalI-NcoI omycin hydrochloride (Sigma, St Louis, MO, USA) or 800 temperature for 2 h. The 50% TCID 50 /ml of cell-free HIV-1 stock was determined by end-point titration as preg/ml G418 (Gibco-BRL). Stable G418 and puromycinresistant CEMSS pools were generally established 2 to 3 viously described. 59 Following virus inoculation, cells were diluted in fresh RPMI-1640 medium, 10% FBS and weeks after transduction. RevM10 protein expression was measured by Rev-specific immunofluorescence as incubated at 37°C. At different time-points thereafter, cell counts were determined and culture supernatants were described. 13, 29 Total cellular RNA was isolated from transduced CEMSS cells using the RNazol B protocol analyzed for HIV-1 p24 antigen concentration. (Ambion, Austin, TX, USA) and analyzed by Northern blot using radiolabeled Rev-specific oligonucleotide (5′ Transduction of primary T cells Buffy coats containing PBL from normal healthy donors CGG GCC TGT CGG GTC CCC TCG GAA TTG GGA GGT GGG 3′) as described. 58 were enriched for CD4 + cells by depleting CD8 + cells using anti-CD8 biotinylated Ab (Becton Dickinson, San José, CA, USA) and streptavidin magnetic dynabeads HIV-1 assays A3.01/ProHygro cells 13 were co-cultivated with the (Dynal, Lake Success, NY, USA). This procedure yielded 90-95% pure CD4 + populations. Cells were stimulated in PA317-based producer cells in transwell plates for 1 to 3 days in the presence of 2 g/ml polybrene. Following a TOC medium (RPMI supplemented with 1 × MEM vitamin solution (Gibco-BRL), insulin-transferrin-sodium transduction, cells were selected in 400 g/ml hygromycin B (Boehringer, Indianapolis, IN, USA) and 800 g/ml selenite supplement (Sigma) and 10% fetal bovine serum (Hyclone, Logan, UT, USA) with PHA (2 g/ml), IL-2 G418 (Gibco-BRL). HIV production in G418 and hygromycin-resistant pools was monitored over a period of 5-(40 U/ml) and irradiated allogeneic peripheral blood mononuclear cells and JY cells as feeders 60 for 3-4 days. 6 days. Cells were washed once with PBS and then seeded in duplicate at a density of 2 × 10 5 cells/ml (5 ml Retroviral vector transduction was performed by centrifugation of 5 × 10 5 cells with 1 ml of supernatant from total volume) in a six-well plate. Each day, after thorough pipetting to ensure homogeneous cultures, 1 ml of cell retroviral producer cells supplemented with 8 g/ml polybrene for 4 h at 1500 g and 34°C. This procedure was suspension was removed and replaced with 1 ml of fresh medium until the cells reached confluency (day 5 or 6).
repeated on 2 consecutive days. The transduced cells were generally enriched by two further rounds of posiCell densities were determined using a Coulter Counter (Model Z1; Coulter, Miami, FL, USA). The supernatants tive selection using anti-Lyt-2 biotinylated Ab (PharMingen, San Diego, CA, USA) and streptavidin were cleared by centrifugation and frozen at −70°C. HIV-1 p24 antigen concentration in the culture supernatants magnetic dynabeads (Dynal). For analysis of retroviral vector expression, approximately 10 6 cells were stimuwas determined on serial dilutions using a commercially available ELISA kit (Dupont-NEN, Boston, MA, USA). lated as above and at different time-points thereafter, small aliquots of cells were removed and double-stained Polyclonal CEMSS cell lines (2 × 10 5 /ml) were inoculated with varying doses (TCID 50 /ml) of HIV-1 HXB3 at room with anti Lyt-2-PE (PharMingen) and anti-human CD25- 
